
BigHat: Leveraging AI to engineer advanced protein therapeutics for complex diseases.
BigHat Biosciences, founded with the mission to revolutionize protein therapeutics, leverages an AI-guided platform to integrate antibody characterization with machine learning. The company's vision is to develop safer and more effective treatments for complex diseases. BigHat focuses on engineering molecules with enhanced functions and biophysical properties, targeting some of the most challenging medical conditions today.
Notable figures affiliated with BigHat include experts in biotechnology and artificial intelligence, though specific names are not provided. The company has achieved significant milestones, including strategic collaborations to advance antibody discovery and design. BigHat's innovative approach has the potential to significantly impact the field of biologics, offering faster and more precise development of therapeutic proteins.

Abterra Biosciences
abterrabio.com

Nabla Bio
nabla.bio

AI Proteins
aiproteinstx.com

TenSixty Biosciences
tensixty.bio

Generate Biomedicines

EpiBiologics
epibiologics.com

Profluent Bio
profluent.bio

Protillion Biosciences
protillion.com

Telis Bioscience
telisbio.com

BioAI Health
bioaihealth.com

Manifold Bio
manifold.bio

Catena Biosciences

BioLoomics
bioloomics.com

Proteinea
proteinea.com

Serotiny
serotiny.bio
Companies similar to BigHat Biosciences include Abterra Biosciences, Nabla Bio, AI Proteins and TenSixty Biosciences.
BigHat Biosciences was founded in 2019.
BigHat Biosciences' headquarters is located in San Mateo, CA, US.
BigHat Biosciences' most recent funding round was for $75M (USD) in July 2022.
As of Jul 20, 2022, BigHat Biosciences has raised a total of $99.3M (USD).
BigHat Biosciences has 92 employees as of Feb 5, 2024.